Prostate Cancer Information and Health Tips by Dr. David Samadi

At an unimaginable young age of 15, young Dr. David Samadi was forced to move from his country of birth to an alien nation. This move was pushed by the Iranian Movement making him seek refuge in Belgium since his birth country was no longer safe. However, more events continued to unravel for him since he had to relocate again to London before finally seeking permanent residence in the United States. While many would give up on their goals due to such happenings, Dr. David Samadi knew that he had to accomplish his dreams. Education was his only way out, and he pulled strings well.

His high school education was excellent, and it enabled him to win a full scholarship for his university education. He studied at Stony Brook University where he opted to learn biochemistry, a course he further advanced by earning an M.D from Stony Brook of Medicine sited in NY back in 1994. Further postgraduate education saw him enroll in Montefiore Medical center for urology studies and he as well studied proctology in 1996 at Albert Einstein College of Medicine. While being mentored by Professor Claude About, Dr. Samadi finalized his training on robotic radical prostatectomy fellowship in 2002, and he also studied proctology at the Memorial Sloan Kettering Cancer Center.

After the long and intensive training, Dr. David Samadi eventually began practicing at Columbia Presbyterian Hospital. Before long, he became the vice chairman of the Urology Department in Mt. Sinai School of Medicine. Such promotions showed his dedication and love for his career, and this can be vividly showed by his creativity and innovativeness of inventing the Samadi Modified Advanced Robotic Treatment (SMART). This technology is particularized for carrying out prostate cancer surgeries, and he has used it to perform quality and successful operations to over 6,000 patients. This is in a short period of about a decade.

Since there are little successful and highly dedicated professionals in the medical field, it is impossible not to notice Dr. David Samadi’s contributions. Accordingly, he has been honored severally. For instance, he was awarded as the most compassionate doctor in 2011, America’s Top Doctors for Cancer in 2014, and he also pocketed the Vitals Patients’ Choice Award in 2014 as well. The New York Magazine also included him in the Best Doctor’s List, supporting the fact that he has made remarkable history of success as a specialized surgeon dealing with prostate, bladder and kidney cancers.

Dr. David Samadi’s Social Media: www.youtube.com/user/RoboticOncology

Clay Siegall Further Supports The Development Of Solutions For Cancer Treatment

Clay Siegall is a clinical scientist who has dedicated his career to developing solutions for the treatment of cancer and other terminal illnesses. As a co-founder of Seattle Genetics, he has helped in the development of the company and the installation of a strong research body, which has in the past one decade managed to come up with new and highly reliable drug pipelines. Seattle Genetics is one of the best performing companies in the healthcare industry and its shares shot up over the past five years due to the development of more drug pipelines and the introduction of the ADC Technology, which is gaining popularity as an option for cancer treatment across the world.

Seattle Genetics prides itself in sponsoring a research team that works on delivering ways of cancer treatment that are devoid of the risks of targeting cells that are not infected. They have been working to ensure all the treatment options they come up with are designed to eliminate the effects of some illnesses without having to induce medication that could potentially destroy neighboring cells. As Clay Siegall cites, the company is projected to record higher returns with their ADC Technology, which was tested and proved to offer all the above benefits. Many specialists prefer using this technology for its reliability and strength in the fight against cancer.

About Clay B. Siegall

Clay B. Siegall is an acclaimed authority in the cancer research industry and this is because of the solutions he has helped to offer to the industry. He has been working with different institutions to propose new methods of cancer treatment as well as championing for the development of drugs for other ailments.

His career is founded on clinical science and research, reason he also founded Seattle Genetics on research and the development of solutions that are reliable and unique. Through his support, the company has increased its partnerships with some of the best research institutes and is on a path towards international placement as the most preferred provider of cancer treatment solutions and technology. Clay Siegall has helped the company to grow since inception in 1998 and as the CEO is looking to leave it at a better position.